Delving into the Latest Updates on Université De Picardie Jules Verne with Synapse

Overview

Tags

Nervous System Diseases

Infectious Diseases

Small molecule drug

Small molecule-drug conjugates

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1
Small molecule-drug conjugates	1

Top 5 Target	Count

TAU(Microtubule-associated protein tau)	1

The purpose of this study is to determine whether the anticipation of pain influences gait control and psychophysiological responses in healthy individuals. Participants will receive a neutral cream described either as potentially painful (experimental group) or inert (control group), and their behavioral and physiological adaptations will be measured during walking tasks.

Start Date01 May 2025

Sponsor / Collaborator

Université De Picardie Jules Verne

NCT06669767

/ RecruitingNot Applicable

Behavioral Indicators of Pain Representation

The goal of this observational study is to compare the postural response to the mental simulation of everyday situations identified as painful in participants with non-specific low back pain and healthy volunteers.
The main questions it aims to answer are :
Do participants with low-back pain show reduced variability in center of pressure displacements compared with non-painful participants when faced with mental simulation of everyday situations identified as painful? Is the postural response correlated with the level of kinesiophobia? Participants will be faced to pictures of everyday situations identified as painful while several physiological measurements (posturography, electromyography, heart rate) are being recorded.

Start Date14 Nov 2024

Sponsor / Collaborator

Université De Picardie Jules Verne

100 Clinical Results associated with Université De Picardie Jules Verne

Login to view more data

0 Patents (Medical) associated with Université De Picardie Jules Verne

Login to view more data

11,022

Literatures (Medical) associated with Université De Picardie Jules Verne

01 Dec 2025·Techniques in Coloproctology

Is a bridge (rod) necessary for loop ileostomy? A phase II randomized control trial

Article

Author: Tartar, L ; Tuech, J-J ; Sabbagh, C ; Bridoux, V ; Browet, F ; Hariz, H ; Demouron, M ; Mauvais, F ; Diouf, M ; Regimbeau, J-M

BACKGROUNDThe value of a bridge in loop ileostomies is debated. We aimed to evaluate whether using a bridge when creating a loop ileostomy can reduce morbidity following an ileostomy.METHODSPatients who had a loop ileostomy after elective colorectal surgery from January 2016 to July 2022 were randomized in this multicenter phase 2 randomized superiority trial. The primary endpoint was the absence of postoperative stomal complications at 2 months and was assessed in a blinded fashion by a stoma therapist. Secondary endpoints were morbidity at 1 month and the STOMA-QOL score at 2 months.RESULTSDuring the study period, 67 patients were randomized to the bridge group and 63 to the no-bridge group. Epidemiological and perioperative data did not differ between the two groups. The stomal complication-free rate was 76% in the bridge group and 67% in the no-bridge group (p = 0.3). There was no difference in the distribution of complications at 1 month according to the Clavien-Dindo score (p = 0.2) or the STOMA-QOL score at 2 months (p = 0.4) between the two groups.CONCLUSIONThe bridge does not reduce the rate of stomatal complications, nor does it appear to reduce patients' quality of life.TRIAL REGISTRATION NUMBERNCT02756273 (May 10, 2016).

01 Aug 2025·Neuropharmacology

Trace amine-associated receptor 1 agonists reduce alcohol drinking and differentially modulate dopamine release in the nucleus accumbens of alcohol preferring mice

Article

Author: Jeanblanc, Jérôme ; Houdant, Charles ; Fouquet, Grégory ; Kruk-Slomka, Marta ; Naassila, Mickaël ; Biała, Grażyna ; Orzelska-Górka, Jolanta ; Lamarche, Mandy ; Debuysscher, Véronique

Current treatments for alcohol use disorder have limited efficacy underscoring the need for novel therapeutic targets. Trace amine-associated receptor 1 (TAAR1) is a promising candidate due to its ability to act as a brake on dopaminergic transmission and alcohol consumption. However, both the relative efficacy of full and partial TAAR1 agonists in reducing alcohol-related behaviors and their underlying mechanisms of action remain unclear. In this study, we evaluated the effects of the full agonist RO5166017 and the partial agonist RO5263397 on alcohol consumption using an intermittent access protocol in alcohol-preferring male C57BL/6JRj mice. Given their distinct pharmacological and electrophysiological properties, we also investigated the effects of these agonists on presynaptic dopaminergic transmission using fast-scan cyclic voltammetry in the nucleus accumbens, a key structure involved in alcohol reinforcement. Full and partial TAAR1 agonists reduced alcohol intake by 25 % and 43 %, respectively. We further report that these agonists exhibit opposite effects on dopamine release under basal conditions, but that these effects are reversed in animals chronically exposed to alcohol. The reversal in dopamine release did not result from alcohol-induced modifications of TAAR1 or D2 receptor expression. Our findings highlight the therapeutic potential of TAAR1 agonists for alcohol addiction and reveal important functional differences between full and partial agonists. Further research is needed to determine the clinical relevance of these distinct pharmacodynamic profiles and optimize TAAR1-targeting pharmacotherapies.

01 Aug 2025·Agriculture, Ecosystems & Environment

Conversion of arable land to perennial bioenergy crops increases soil organic carbon stocks on the long term

Author: Marsac, Sylvain ; Mary, Bruno ; Ferchaud, Fabien

Perennial C4 bioenergy crops can combine high productivity and low input requirements.However, their impact on soil organic carbon (SOC) stocks remains uncertain.The aim of this study was to assess the long-term impact of converting arable land to perennial bioenergy crops on SOC stocks for two crop species (miscanthus and switchgrass) and several crop management practices (nitrogen fertilization, harvest date and irrigation).We analyzed two long-term experiments located in northern and southern France.Both sites were sampled initially and after 12 or 13 years.SOC stocks were calculated at equivalent soil mass in each site and δ¹³C measurements were used to calculate changes in "new" and "old" SOC stocks.SOC stocks in the old ploughed layer increased significantly in both sites but most of the SOC storage occurred in the topsoil layer (∼0-5 cm).SOC storage rate was fairly similar between miscanthus and switchgrass but was much greater in the southern site than in the northern site (0.96 vs 0.26 t C ha^-1 yr^-1).This larger storage rate was mainly explained by higher carbon inputs, as suggested by the higher accumulation rate of new SOC (1.41 vs 0.86 t C ha^-1 yr^-1).No significant effect of the management practices on the SOC change rate could be detected, but early harvest systematically reduced SOC storage compared to late harvest (by 33 % for miscanthus and 12 % for switchgrass).Higher carbon inputs due to late harvest or irrigated conditions were partly compensated by a higher old SOC decrease.

100 Deals associated with Université De Picardie Jules Verne

Login to view more data

100 Translational Medicine associated with Université De Picardie Jules Verne

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 10 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

Preclinical

Login to view more data